4//SEC Filing
Wu Charles C 4
Accession 0001140361-23-054511
CIK 0001124105other
Filed
Nov 21, 7:00 PM ET
Accepted
Nov 22, 7:20 PM ET
Size
5.9 KB
Accession
0001140361-23-054511
Insider Transaction Report
Form 4
Wu Charles C
DirectorChief Executive Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-11-20+170,417→ 170,417 totalExercise: $0.75Exp: 2030-10-31→ Common Stock (170,417 underlying)
Footnotes (2)
- [F1]Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.
- [F2]These options are vested in full.
Documents
Issuer
GYRE THERAPEUTICS, INC.
CIK 0001124105
Entity typeother
Related Parties
1- filerCIK 0001985621
Filing Metadata
- Form type
- 4
- Filed
- Nov 21, 7:00 PM ET
- Accepted
- Nov 22, 7:20 PM ET
- Size
- 5.9 KB